US2016331747A1PendingUtilityA1

Pharmaceutical formulation for reducing frequency of urination and method of use thereof

62
Assignee: WELLESLEY PHARMACEUTICALS LLCPriority: Jul 8, 2010Filed: Jul 25, 2016Published: Nov 17, 2016
Est. expiryJul 8, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:David A. Dill
A61K 31/192A61K 31/167A61K 31/4985A61K 31/616A61K 9/284A61K 9/08A61K 9/0019A61K 31/122A61K 9/2846A61K 9/2866A61K 31/12A61K 31/437A61K 31/405A61K 45/06A61K 31/216
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for reducing frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Claims

exact text as granted — not AI-modified
1 . A method for reducing frequency of urination in a subject, comprising:
 administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of one or more analgesic agents and an effective amount of tadalafil,   wherein said pharmaceutical composition is formulated for immediate release or delayed release or extended release.   
     
     
         2 . The method of  claim 1 , wherein said pharmaceutical composition is formulated for immediate release. 
     
     
         3 . The method of  claim 1 , wherein said pharmaceutical composition is formulated for extended release. 
     
     
         4 . A method for reducing frequency of urination in a subject, comprising:
 administering to a subject in need thereof a pharmaceutical composition comprising:   an active ingredient comprising one or more analgesic agents in an amount of 1-2000 mg per agent; and   an effective amount of an inhibitor of phosphodiesterase type 5 (PDE, 5 inhibitor),   wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium; indomethacin, nabumetone, and acetaminophen,   wherein said pharmaceutical composition is formulated for immediate release or delayed release or extended release.   
     
     
         5 . The method of  claim 4 , wherein said pharmaceutical composition is formulated for delayed release. 
     
     
         6 . The method of  claim 4 , wherein said pharmaceutical composition is formulated for extended release. 
     
     
         7 . The method of  claim 6 , wherein said pharmaceutical composition is formulated for immediate release. 
     
     
         8 - 10 . (canceled) 
     
     
         11 . A method for reducing the frequency of urination in a subject, comprising:
 administering to a subject in need thereof a pharmaceutical composition comprising:   an effective amount of a first active ingredient comprising one or more analgesic agents and tadalafil; and   an effective amount of a second active ingredient comprising one or more agents selected from the group consisting of analgesic agents, antimuscarinic agents, antidiuretics, spasmolytics, PDE 5 inhibitors and zolpidem,   wherein said pharmaceutical composition is formulated for immediate release or delayed release or extended release.   
     
     
         12 . The method of  claim 11 , wherein said pharmaceutical composition is further coated with an enteric coating. 
     
     
         13 . The method of  claim 11 , wherein said first active ingredient comprises acetaminophen. 
     
     
         14 . The method of  claim 11 , wherein said first active ingredient further comprises an antimuscarinic agent, an antidiuretic, a spasmolytic or zolpidem. 
     
     
         15 - 20 . (canceled) 
     
     
         21 . The method of  claim 1 , wherein said pharmaceutical composition is formulated for delayed release. 
     
     
         22 . The method of  claim 11 , wherein said pharmaceutical composition is formulated for immediate release. 
     
     
         23 . The method of  claim 11 , wherein said pharmaceutical composition is formulated for delayed release. 
     
     
         24 . The method of  claim 11 , wherein said pharmaceutical composition is formulated for extended release. 
     
     
         25 . A method for reducing frequency of urination in a subject, comprising:
 administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of one or more analgesic agents and an effective amount of a PDE 5 inhibitor,   wherein the pharmaceutical composition comprises an immediate-release component and an extended release component.   
     
     
         26 . The method of  claim 25 , wherein the immediate-release component comprises the one or more analgesic agents, and wherein the extended release component comprises the PDE 5 inhibitor. 
     
     
         27 . The method of  claim 25 , wherein the one or more analgesic agents comprises acetaminophen. 
     
     
         28 . The method of  claim 27 , wherein the one or more analgesic agents comprises acetaminophen and a non-steroidal anti-inflammatory drug. 
     
     
         29 . The method of  claim 25 , wherein the PDE 5 inhibitor is tadalafil.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.